TPPs are useful to align the end-users needs with the targets and specifications that product developers should meet. TPPs should state the clinical purpose of a test, goal to be met (e.g. start treatment), target population, implementation level in the healthcare system, and likely end-users (unpublished observations).
In 2013, participants at a TB Modelling and Analysis Consortium (TB MAC) meeting on diagnostics identified a list of diagnostic needs that could be developed into TPPs (unpublished observations). Using this list of nine potential TPPs ( fig. 1 ), we conducted a priority-setting exercise to identify the highest priority tests for TPP development and investment in research and development. For each of the potential TPPs, hereafter called TPPs, 10 criteria were used to set priorities, including prioritisation by key stakeholders, potential impact of the test on TB transmission, morbidity and mortality, market potential and implementation and scalability of the test.
Five different predefined expert groups (o10 individuals each) were asked to rate one or two criteria in their field of expertise. 10 patient and community advocates, which included members of civil society groups such as the Treatment Action Group and Global TB Community Advisory Board, and 11 field practitioners/clinicians, primarily surveyed by Médecins Sans Frontières, rated the prioritisation for their respective stakeholders group. 10 experts from national TB programmes in 10 countries rated the prioritisation from a programmatic perspective and the potential for scale up. 11 TB modellers, mostly members of TB MAC, rated the potential impact of tests on reducing TB incidence and TB morbidity and mortality in the medium term (5 years). 11 market and technical experts, including donor agency representatives, rated the potential global market size for products when fully scaled-up and their potential to reach the market in the next 5 years.
Experts were asked to rate each relevant criterion as high, medium or low priority and maximally rate five TPPs as high per criterion. The answer most often given in each group was taken as their consensus. When two answers were mentioned equally, both were reported. Priorities according to researchers and the test's potential to be used as a point-of-care-test, according to the definition proposed by the TB MAC meeting participants (unpublished observations) and PAI et al. [12] , were rated by our team, in conjunction with recent publications that addressed research priorities [13, 14] . The final priority rank of the TPPs was determined by the sum score for all 10 criteria, where 3, 2, 1, 2.5 and 1.5 points were attributed for consensus answers that were high, medium, low, medium-high or low-medium, respectively.
A response was received from 53 (78%) out of 68 contacted stakeholders. Figure 1 shows the consensus answers for all TPPs. A rapid, sputum-based, molecular test for microscopy centres (with the option of addon DST cartridge) ranked highest (score 29.5), followed by a rapid biomarker-based, instrument-free test for non-sputum samples (that also detects childhood and extrapulmonary TB) (score 28). The low likelihood of the latter test to reach the market in the next 5 years resulted in its slightly lower overall score compared to the former. In particular, for the biomarker-based test, there was a high degree of agreement within each group; 60% (national TB programmes) and 91% (patient and community advocates and field practitioners) of responders in these groups rated it highly.
TPPs that ranked 3 through to 5 in priority were tests that would not directly confirm TB, but would be used as rule-in (systematic screening test) or rule-out tests (triage test or rule-out TB test for HIV-infected individuals). These TPPs ranked lower on their ability to reduce TB morbidity and mortality or TB incidence, and their market potential was thought to be less than that of some other TPPs. In addition, there was more heterogeneity in rates given by stakeholders.
The lowest ranked TPPs included a predictive LTBI test (ranked sixth), a test for TB treatment response (seventh), a multiplexed test that simultaneously detects active TB and other infectious diseases (eighth), and a centralised and high-throughput DST for current and new treatment regimens (ninth). 4 Médecins Sans Frontières Access Campaign, Geneva, Switzerland.
